It offers concrete data that can help identify which spheres of cognition are being affected
Allows easier access to cognitive assessments with good efficacy in a reasonable time frame.
Longitudinal follow up with repeat testing sessions is also one of its strengths
It's a peer-reviewed test that provides results that can be used to help improve care.
It allows for numeric and graphic comparisons both to 'normal' scores and also previous tests of same individual.
It lends the examiner credence when showing the results in black and white
Allows a more objective cognitive assessment and the results are often not obvious on interview
This is a valuable tool that gives insight into current cognitive levels
Results are immediately available and the data can be instantly absorbed.
People of a wide age range are able to perform this test with minimal to no computer knowledge
people appreciate having a time-efficient method of evaluating their cognition.
It's a convenient, on-site tool that provides a snapshot with a fair level of detail pertaining to one's cognitive abilities.
Provides a convenient, objective, cognitive assessment at low cost.
It is easy to use - it can be very time savvy
A more objective assessment of cognitive function
Good tool for establishing a baseline and tracking progress.
It creates an objective report.
Contact Us

NEWS - August 19, 2013

Research Featuring NeuroTrax Tests Selected as Editor’s Pick by MS Discovery Forum

Research using NeuroTrax tests to measure cognitive function in a large group of multiple sclerosis (MS) patients was selected as an Editor's Pick by the Executive Editor of the MS Discovery Forum ( The peer-reviewed article, published in the open-access PLoS One journal, reports on a study using NeuroTrax tests to model the relationship between cognitive function and disease duration in 1,500 patients with disease duration up to 30 years. In the study, Professor Anat Achiron of the Sheba Medical Center (Tel-Hashomer, Israel) and colleagues found that cognitive function measured by NeuroTrax tests differed from expected normal distribution beginning at five years from onset, most prominently in executive function. This is taken to suggest the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.

NeuroTrax provides research services to pharmaceutical and medical device companies as well as academic investigators in need of validated and standardized cognitive measures for their clinical trials. Services include data collection, data analysis, investigator training, customization, and software services.

Article on PLoS One
News Story on MS Discovery Forum
  Search    About    Contact Us